Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$1.02
+2.0%
$3.11
$0.68
$7.29
$97.99M0.7913.30 million shs6.35 million shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$6.90
+3.9%
$5.14
$3.61
$9.20
$78.27M1.72123,263 shs417,502 shs
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.09
$2.09
$1.34
$2.17
$104.79M0.77838,767 shsN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.55
-3.7%
$0.39
$0.22
$4.79
$23.74M-0.057.86 million shs981,959 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+2.00%-3.77%-0.49%-82.97%-62.50%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+3.92%+22.78%+52.32%+49.67%-23.42%
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00%0.00%-0.48%+1.46%+14.84%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-3.74%-13.63%+76.25%+60.32%-77.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$1.02
+2.0%
$3.11
$0.68
$7.29
$97.99M0.7913.30 million shs6.35 million shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$6.90
+3.9%
$5.14
$3.61
$9.20
$78.27M1.72123,263 shs417,502 shs
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.09
$2.09
$1.34
$2.17
$104.79M0.77838,767 shsN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.55
-3.7%
$0.39
$0.22
$4.79
$23.74M-0.057.86 million shs981,959 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+2.00%-3.77%-0.49%-82.97%-62.50%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+3.92%+22.78%+52.32%+49.67%-23.42%
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00%0.00%-0.48%+1.46%+14.84%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-3.74%-13.63%+76.25%+60.32%-77.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.00
Hold$23.252,179.41% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
2.33
Hold$47.00581.16% Upside
HilleVax, Inc. stock logo
HLVX
HilleVax
2.00
Hold$2.00-4.31% Downside
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.75
Reduce$3.38511.97% Upside

Current Analyst Ratings Breakdown

Latest LPTX, DTIL, HLVX, and ATYR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/15/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Jones Trading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/15/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/15/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweightEqual Weight
9/15/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
9/15/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform
(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$230K434.56N/AN/A$0.83 per share1.23
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$68.70M1.18N/AN/A$6.87 per share1.00
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/A$3.10 per shareN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)
HilleVax, Inc. stock logo
HLVX
HilleVax
-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%11/6/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.58N/AN/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)

Latest LPTX, DTIL, HLVX, and ATYR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2025Q3 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.24N/AN/AN/AN/AN/A
11/6/2025Q3 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.19N/AN/AN/AN/AN/A
11/3/2025Q3 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.31N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.29-$0.40-$0.11-$0.40N/AN/A
8/7/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18-$0.22-$0.04-$0.22N/AN/A
8/7/2025Q2 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million
8/6/2025Q2 2025
HilleVax, Inc. stock logo
HLVX
HilleVax
-$0.14-$0.11+$0.03-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
5.63
5.63
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.66
5.18
5.18
HilleVax, Inc. stock logo
HLVX
HilleVax
N/A
26.39
26.39
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
1.34
1.34

Institutional Ownership

CompanyInstitutional Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%
HilleVax, Inc. stock logo
HLVX
HilleVax
86.42%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%

Insider Ownership

CompanyInsider Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.50%
HilleVax, Inc. stock logo
HLVX
HilleVax
24.90%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5397.99 million94.36 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
20011.79 million11.26 millionNo Data
HilleVax, Inc. stock logo
HLVX
HilleVax
2050.14 million37.66 millionNot Optionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable

Recent News About These Companies

Leap Therapeutics, Inc. (LPTX) - Yahoo Finance
H.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$1.02 +0.02 (+2.00%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$1.01 -0.01 (-0.49%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$6.90 +0.26 (+3.92%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$6.90 0.00 (0.00%)
As of 10/17/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

HilleVax stock logo

HilleVax NASDAQ:HLVX

$2.09 0.00 (0.00%)
As of 09/17/2025

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.55 -0.02 (-3.74%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$0.57 +0.02 (+2.99%)
As of 10/17/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.